Overview
Use of Activated Recombinant Human Factor VII in Cardiac Surgery
Status:
Terminated
Terminated
Trial end date:
2007-11-01
2007-11-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This trial is conducted in Africa, Asia, Europe, South America and the United States of America (USA). The trial is planned to investigate the safety and efficacy of NovoSeven® in the management of post-operative bleeding in patients following cardiac surgery.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Novo Nordisk A/S
Criteria
Inclusion Criteria:- Post-operative bleeding according to pre-defined criteria for critical bleeding